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Abstract 
Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are two 
neurodegenerative diseases with clinical, genetic and pathological overlap. As such, they 
are commonly regarded as a single spectrum disorder, with pure FTD and pure ALS 
representing distinct ends of a continuum. Dysfunctional endo-lysosomal and autophagic 
trafficking, leading to impaired proteostasis is common across the FTD-ALS 
spectrum.  These pathways are, in part, mediated by CHMP2B, a protein that coordinates 
membrane scission events as a core component of the ESCRT machinery. Here we review 
how ALS and FTD disease causing mutations in CHMP2B have greatly contributed to our 
understanding of how endosomal-lysosomal and autophagic dysfunction contribute to 
neurodegeneration, and how  in vitro and in vivo models have helped elucidate novel 
candidates for potential therapeutic intervention with implications across the FTD-ALS 
spectrum.   
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Introduction. 
Frontotemporal Dementia (FTD) is a common cause of early-onset dementia with a typical 
age of onset under 65 years. FTD is frequently used as an umbrella term referring to a 
heterogeneous group of neurodegenerative disorders associated with Frontotemporal lobar 
degeneration (FTLD), a progressive atrophy of the frontal and temporal cortices. These 
include behavioural variant FTD (bvFTD), primary progressive aphasia and semantic 
dementia. Amyotrophic Lateral Sclerosis (ALS) is the most common form of motor neurone 
disease and is characterised by the progressive atrophy and dysfunction of upper and lower 
motor neurons. FTD and ALS show significant genetic, neuropathological and clinical 
overlap with approximately 14% of FTD patients displaying concomitant motor neurone 
disease (Phukan et al., 2012). This has led to the general consensus that FTD and ALS 
represent a continuum of a single spectrum disorder. Impaired proteostasis and 
dysfunctional endosomal-lysosomal and autophagic trafficking are common across the FTD-
ALS spectrum. Here we review how FTD and ALS disease causing mutations in Charged 
Multivesicular Body Protein 2B (CHMP2B), have greatly contributed to our understanding of 
how endosomal-lysosomal and autophagic dysfunction contribute to neurodegeneration, with 
implications across the FTD-ALS spectrum.   
 
CHMP2B Structure and Function. 
CHMP2B is an evolutionary conserved, 213 amino acid protein encoded by the CHMP2B 
gene (Figure 1A-B). It is an essential component of the Endosomal Sorting Complex 
Required For Transport III (ESCRT-III), which with ESCRTs 0, I and II play a fundamental 
role in membrane scission events during the biogenesis of multivesicular bodies (MVBs) and 
sorting of endosomal cargos (Figure 1C). The ESCRT machinery also controls other 
fundamental cellular processes including cytokinesis (Bhutta et al., 2014; Caballe and 
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Martin-Serrano, 2011), viral exocytosis (Lata et al., 2009), endo/lysosomal repair (Radulovic 
et al., 2018) and autophagy (Rusten and Stenmark, 2009). CHMP2B is a core component of 
the ESCRT-III complex, which plays a part in all these processes. It has been shown to be 
expressed in multiple human tissues, in all major regions of the brain (Skibinski et al., 2005) 
and in every cell type in the central nervous system (CNS)(Cahoy et al., 2008; Zhang et al., 
2014). 
 
CHMP2B contains two N-terminal coiled coil domains (1-50 and 120-150) (Figure 1B), 
peptide repeats found throughout all kingdoms of life (Liu and Rost, 2001). Coiled coil 
domains are purported to function as molecular scaffolds, mediating events including vesicle 
tethering (Truebestein and Leonard, 2016; Witkos and Lowe, 2015) and playing an integral 
role in communicating conformational change within a cell (Liu et al., 2006; Redwine et al., 
2012). Though limited in sequence homology, the 11 human CHMP proteins show various 
commonalities. They are all components of the ESCRT-III complex (Morita, 2012; Olmos 
and Carlton, 2016), are  of a similar size, have predicted coiled-coil domains and importantly 
display highly asymmetric charge distribution, with negatively charged basic residues at the 
N-terminus and acidic positively charged residues at the C-terminus (Carlton and Martin-
Serrano, 2009; Howard et al., 2001; Lata et al., 2009). The C-terminal region of CHMP2B 
contains a MIT-interacting motif (MIM) (Figure 1B) which is essential for interaction with 
proteins containing corresponding microtubule interacting and transport (MIT) domains. 
Vps4 was identified as a putative binding partner for CHMP2 proteins (Babst et al., 1998). 
Mutations in Vps4 (Finken-Eigen et al., 1997) and genetic silencing of CHMP genes in yeast 
disrupted endosomes, identifying profound deficits in vesicle trafficking (Howard et al., 
2001).  This regulation was originally thought to be mediated by the N-terminal coiled coil 
regions of the CHMP proteins, however GST-pulldown assays showed that Vps4 interacts 
with the acidic C-terminus of CHMP proteins (Scott et al., 2005). The MIM domain of 
CHMP2B is composed of a single helix that binds between two of the 3 helices in the MIT 
domain of Vps4 and is essential for ESCRT function (Krasniak and Ahmad, 2016).  
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The most well described role of CHMP2B is during its regulation of MVB biogenesis (Figure 
1C). Invagination and budding off of the endosomal limiting membrane allows the formation 
of MVB intraluminal vesicles, into which ubiquitinated proteins are internalised and sorted for 
degradation via the lysosome, or trafficking back to the plasma membrane (Babst, 2006; 
Lata et al., 2009; Schmidt and Teis, 2012). This process requires coordinated activation of 
ESCRTs 0-III and the Vps4 complex. Briefly, ESCRT-0, composed of HGS (Vps27) and 
STAM (HSE) heterodimers, localizes to endosomes through an interaction with 
phosphatidylinositol-3-phosphate (PI3P) (Morita, 2012; Olmos and Carlton, 2016; Schmidt 
and Teis, 2012). When localized to endosomes, ESCRT-0 binds to ubiquitinated proteins 
initiating the first stage of the process. The presence of ESCRT-0 on endosomes triggers the 
recruitment of the cytosolic ESCRT-I, a soluble hetero-tetramer consisting of TSG101 
(Vps23), Vps28, Vps37(A–D) and MVB12. ESCRT-I also binds ubiquitinated proteins and 
then interacts with ESCRT-II. ESCRT-II, another hetero-tetrameric complex consisting of 
Vps36, SNF8 (Vps22) and two Vps25 molecules, causes membrane invagination and 
triggers the stepwise assembly of the core regulators of this process, ESCRT-III and the 
Vps4 complex. ESCRT-0-II represent stable cytoplasmic complexes however the assembly 
of ESCRT-III is transient and coordinated via sequential activity of ESCRT-III proteins 
(Morita, 2012; Schmidt and Teis, 2012). Firstly, CHMP6 (Vps20) is activated by ESCRT-II, 
triggering the oligomerization of CHMP4 (Snf7) (Schmidt and Teis, 2012). Recent work from 
Bertin et al., (2020) demonstrated that CHMP4B filaments, in the absence of other ESCRT-
III proteins, bind preferentially to flat membranes (Bertin et al., 2020). CHMP3/Vps24 then 
terminates the assembly of ESCRT-III filaments on endosomal membranes and recruits 
CHMP2A and B, which complete the assembly of the core components of the ESCRT-III 
complex (Schmidt and Teis, 2012). In contrast to CHMP4B, CHMP2A/B and CHMP3 prefer 
positively curved membranes (Bertin et al., 2020).   
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Activation of CHMP2A/B encourages the recruitment of the Vps4 complex. This complex 
consists of the AAA-(ATPases Associated with diverse cellular Activities) ATPase Vps4, and 
its cofactor Vta1. During unstimulated conditions, CHMP2B exists in an auto-inhibited state, 
with the acidic C-terminus bound to the basic N-terminus, masking the CHMP2B domains 
that interact with members of the ESCRT-III complex (Krasniak and Ahmad, 2016; Schmidt 
and Teis, 2012). Upon activation, the N-terminal MIT domain of Vps4 binds the C-terminal 
MIM domain of CHMP2B, which begins the process of recruiting the Vps4 complex to 
ESCRT-III. When Vps4 assembles on ESCRT-III, it forms a dodecamer, a ring shaped 
oligomer with a central pore. The binding of Vta1 to Vps4 activates its ATPase activity and 
via the physical interaction with CHMP2B, using energy generated from ATP, Vps4 
constricts the neck of intraluminal vesicles, coordinating a scission event,  freeing vesicle 
cargoes into the lumen of the MVB (Krasniak and Ahmad, 2016; Morita, 2012; Olmos and 
Carlton, 2016; Schmidt and Teis, 2012). As such, CHMP2B and Vps4 are critical for this 
process. Vps4 then regulates ESCRT-III disassembly, which dissociates into inactive 
protomers (Schmidt and Teis, 2012) in order to coordinate the next round of MVB 
biogenesis.  
 
ESCRT-III has also been identified as a core regulator of endo/lysosomal repair. L-leucyl-L-
leucine O-methyl ester (LLOME) is commonly used to rupture endolysosomes (Aits et al., 
2015; Maejima et al., 2013; Thiele and Lipsky, 1990). LLOME is cell permeable and 
accumulates in the lumen of acidified organelles, where through a reaction with the 
lysosomal enzyme cathepsin C, is condensed into a membranolytic polymer. The damage to 
lysosomal membranes triggers the rapid recruitment of ESCRT proteins, which accumulate 
on damaged lysosomes and facilitate their repair. This protective response to lysosomal 
disruption precedes lysophagy and promotes cell survival (Radulovic et al., 2018). 
 
Along with regulating lysosomal repair, ESCRT-III has also been described as a regulator of 
macroautophagy (Feng et al., 2014; Krasniak and Ahmad, 2016; Lee et al., 2007; Lu et al., 
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2013). This cellular event, where autophagosomes coordinate the bulk degradation and 
recycling of cytoplasmic material and organelles through fusion with the lysosome, 
represents a fundamental process across species (Feng et al., 2014). Loss of ESCRT genes 
has been shown to cause accumulation of autophagosomes in yeast (Roudier et al., 2005), 
Drosophila (Rusten et al., 2007) and mammals (Hara et al., 2006; Komatsu et al., 2006) 
suggesting that autophagosomal fusion with the lysosome requires ESCRT subunits. This 
has been further demonstrated in mammalian neurons, where loss of CHMP4B/Snf7-2 
causes autophagosome accumulation, as well as dendritic retraction and neuronal cell death 
(Lee et al., 2007). This implicates ESCRT function in the regulation of autophagy in neurons 
and shows that basal levels of autophagy are essential for the maintenance of neuronal 
health. 
 
Consistent with the regulation of these fundamental cellular processes, ESCRT proteins 
have been demonstrated to regulate key processes within both the developing and adult 
nervous system. This includes sorting of synaptic proteins, neurite outgrowth and dendrite 
and axon pruning (reviewed in Sadoul et al., 2018). Of particular importance to 
neurodegenerative disease, is the observation that CHM2PB and its association with 
CHMP4B, is critical to the maintenance of mushroom shaped spines. Depletion of CHMP2B 
decreases dendrite length and spine volume, resulting in a concomitant reduction of synaptic 
efficacy, in a chemical model of long-term potentiation (LTP) (Chassefeyre et al., 2015; 
Sadoul et al., 2018). As previously mentioned, genetic silencing of CHMP proteins also 
disturbs endosomal generation and trafficking. Defective endosomal-lysosomal signaling has 
been described in many neurodegenerative diseases, including ALS and FTD (Burk and 
Pasterkamp, 2019; Lee et al., 2007; Nixon, 2005; Sasaki, 2011). Most recently in 
Alzheimer’s disease, where knockdown of CHMP6 and double knockdown of CHMP2A+B 
accelerated the propagation of pathological tau in vitro (Chen et al., 2019). Here, we focus 
on mutations in CHMP2B, how these mutations affect CHMP2B function and what this 
means in the context of FTD and ALS. 
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CHMP2B in FTD and ALS. 
The identification of CHMP2B as a causative FTD loci came in 2005, when a Danish cohort 
diagnosed with a familial pre-senile dementia, distinct from Alzheimer’s (Gydesen et al., 
1987), were shown to have a rare autosomal dominant heterozygous mutation in the 
CHMP2B gene (Skibinski et al., 2005). The disease causing mutation was identified as a G-
to-C transition within the splice acceptor site of the 6th, and final, exon of CHMP2B. The 
resultant, aberrant mRNA splicing was shown to produce two novel transcripts; CHMP2B〉10 
and CHMP2BIntron5, identified in the brains of FTD patients at approximately 10% and 35% of 
wild-type CHMP2B transcript levels, respectively. Translation of these transcripts leads to 
the formation of two C-terminally truncated proteins with the terminal 36 amino acids 
replaced with either a valine residue (CHMP2BIntron5 (M178V)) or a 29 amino acid nonsense 
sequence (CHMP2B〉10) (Figure 1B). Subsequent C-terminal truncating mutations identified 
include a novel missense mutation, CHMP2BQ165X, in a Belgian patient (van der Zee et al., 
2008) and CHMP2BR186X in two asymptomatic siblings of a familial, autosomal dominant FTD 
patient (Momeni et al., 2006). A rare sporadic mutation, CHMP2BD148Y, has also been 
identified in semantic dementia (Skibinski et al., 2005). Prior to the identification of specific 
CHMP2B mutations, the disease-associated gene in the original Danish family was mapped 
to the pericentromeric region of chromosome 3, leading to the designation of CHMP2B-
related FTD as chromosome 3-linked frontotemporal dementia (FTD3) (Brown et al., 1995; 
Gydesen et al., 2002).  Mutations in CHMP2B as a cause of FTD-ALS are uncommon, 
however different mutations have now been identified across the FTD-ALS spectrum, 
including FTD (Ghanim et al., 2010; Skibinski et al., 2005; van der Zee et al., 2008), ALS 
(Cox et al., 2010; Narain et al., 2018; Parkinson et al., 2006; van Blitterswijk et al., 2012) and 
FTD with ALS (Parkinson et al., 2006). A number of CHMP2B mutations (I29V, T104N and 
Q206H) have been identified in progressive muscular atrophy (PMA), a rare form of motor 
neuron disease (Figure 1A) (Cox et al., 2010). Further mutations have been observed in 
related neurodegenerative diseases falling outside the FTD-ALS spectrum, including 
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corticobasal degeneration (van der Zee et al., 2008) and Alzheimer’s disease (Hooli et al., 
2014).  
 
Although the mutations in CHMP2B are rare, the importance of CHMP2B to the FTD-ALS 
spectrum does not lie in the number of cases, but instead in the distinctive pathology 
observed. In contrast to the majority of FTD causative loci, mutations in CHMP2B are 
associated with TDP-43 negative, ubiquitin and/or p62 positive inclusions (Holm et al., 
2007). As such, they are commonly categorised as a distinct pathological subtype, FTLD-
UPS (FTLD-Ubiquitin Proteasome System). Despite the lack of TDP-43 positive inclusions in 
CHMP2BIntron5 patients or models, the ESCRT machinery and MVBs have been implicated in 
the clearance of TDP-43 (Filimonenko et al., 2007). Both TSG101 and CHMP3 knockdown 
result in TDP-43 accumulations colocalising with ubiquitin and p62 positive cytoplasmic 
inclusions in HeLa cells (Filimonenko et al., 2007). This was not observed in CHMP2BIntron5 
or CHMP2B〉10 cells. Furthermore, a recent study demonstrated that knockdown of CHMP2B 
was sufficient to alleviate toxicity associated with overexpression of TDP-43 in both 
Drosophila and mammalian cell models (Sun et al., 2020). CHMP2B knockdown alleviated 
the perturbed, rough eye phenotype observed when human TDP-43 (hTDP-43) was 
expressed in the fly eye, as well as reduced longevity and impaired climbing ability when 
hTDP-43 was pan-neuronally expressed (Sun et al., 2020). In contrast to previous findings, 
Sun et al., also demonstrated increased TDP-43 hyperphosphorylation and insolubility in 
CHMP2BIntron5 models. This was associated with reduced turnover of Casein Kinase 1 alpha 
1 (CSNK1A1/CK1), which is known to phosphorylate TDP-43 (Hasegawa et al., 2008; 
Kametani et al., 2009; Sun et al., 2020). The presence of hyperphosphorylated TDP-43 in 
cellular CHMP2BIntron5 models is a distinct parallel to the absence of TDP-43 staining in 
CHMP2BIntron5 patient tissue. Nonetheless, given that endocytosis regulates TDP-43 toxicity 
and turnover (Liu et al., 2017), CHMP2BIntron5 perturbs endocytic trafficking (Urwin et al., 
2010) and knockdown of CHMP2B prevents TDP-43 toxicity; it is clear that there is a 
complex relationship between CHMP2B and TDP-43 which warrants further investigation. 
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Furthermore, these observations suggest potentially independent mechanisms by which the 
ESCRT machinery may contribute towards both TDP-43 positive and negative forms of FTD-
ALS, highlighting the importance of understanding the role of the ESCRT machinery in 
neurodegeneration across the FTD-ALS spectrum.   
 
CHMP2B mutations are largely characterised by perturbations to normal endosomal-
lysosomal and autophagic trafficking, resulting in the aberrant accumulation of enlarged 
endosomes and autophagic organelles (Lee et al., 2007; Nielsen et al., 2012; Skibinski et al., 
2005; Urwin et al., 2010; West et al., 2020; Zhang et al., 2017). However, an increasing body 
of evidence highlights the importance of CHMP2B in interconnected signalling cascades 
linking proteostasis, immune signalling, redox biology and neuronal homeostasis. These 
observations have been determined by a number of in vitro and in vivo models that have 
provided insights into the mechanisms underpinning CHMP2B-related neurodegeneration, 
with relevance across the FTD-ALS spectrum. 
 
Endosomal-lysosomal dysfunction. 
The pathogenic CHMP2BIntron5 mutation has been extensively modelled in vitro. The earliest 
reports monitored the expression of N-terminal myc-tagged CHMP2BIntron5 and CHMP2B〉10 
in PC12 cells (Skibinski et al., 2005). Transient transfection of PC12 cells revealed that wild 
type CHMP2B shows a diffuse cytosolic distribution (Skibinski et al., 2005). In contrast 
CHMP2BIntron5 and CHMP2B〉10 induced aberrant punctate cytoplasmic inclusions. Large 
cytoplasmic inclusions in CHMP2BIntron5 cells stained positive for the endosomal/lysosomal 
marker CD63.  Fluorescent dextran, used as an exogenous marker of the endosomal 
pathway, also accumulated in the larger inclusions of CHMP2BIntron5 positive cells. 
CHMP2BIntron5 cells also displayed smaller inclusions, however these showed minimal 
dextran or CD63 co-localisation (Skibinski et al., 2005). In contrast, only small inclusions 
partially colocalizing with dextran or CD63 were observed in CHMP2B〉10 cells (Skibinski et 
al., 2005). Accumulation of large endosomes has been observed in a number of CHMP2B 
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FTD models (Table 1) including rat primary neurons transfected with CHMP2BIntron5 (Lee et 
al., 2007; West et al., 2020), patient derived fibroblasts and cortical tissue (Urwin et al., 
2010). The accumulation of aberrant endosomes associated with CHMP2BIntron5 is due to its 
failure to dissociate from CHMP4B during MVB biogenesis (Lee et al., 2007). 
Immunoprecipitation of CHMP4B from HEK293 cells revealed 3.5x more CHMP2BIntron5 
bound to CHMP4B than wild type CHMP2B (Lee et al., 2007). Ectopically expressed 
CHMP2BIntron5 sequestered CHMP4B into Rab7 positive vesicular structures, indicating that 
dysfunctional ESCRT-III assembles on late endosomes (Lee et al., 2007). Expression of a 
dominant negative Vps4 induced a similar phenotype, indicating that dysfunctional assembly 
and disassembly of ESCRT-III may contribute to neuronal cell loss (Lee et al., 2007). 
In primary neurons CHMP2BIntron5 aggregates also co-localise with Rab4, Rab5 and Rab7, 
markers of recycling, early and late endosomes (West et al., 2020). The localisation of these 
aggregates is similar to other CHMP2B mutations (T104N) which, although less toxic, also 
co-localise with Rab5 and Rab7 positive endosomes (Han et al., 2012). Accumulation of 
recycling, early and late endosomes was also observed in Drosophila models pan-neuronally 
expressing CHMP2BIntron5 under the control of the pan-neuronal driver, neuronal 
synaptobrevin (nSyb) Gal4 (West et al., 2020). In both rat primary neuron and Drosophila 
models, aberrant accumulation of ubiquitinated proteins, a hallmark of FTD-3, was also 
observed (Lee et al., 2007; West et al., 2020). 
The first CHMP2BIntron5 mouse model was described by Ghazi-Noori et al in 2012. 
Expression of human CHMP2BIntron5 using the hamster prion promoter, driving strong 
expression in the hippocampus, thalamus and cerebellum Purkinje cells, recapitulated 
aspects of FTD3, including accumulation of ubiquitin/p62 positive aggregates, negative for 
TDP-43 (Ghazi-Noori et al., 2012). Subsequent studies identified a significant accumulation 
of autofluorescent aggregates, distinct from p62 aggregates, in the thalamus (significant vs 
CHMP2B Wild type and non-transgenic controls at 12 months) and cortex (significant vs 
CHMP2B Wild type and non-transgenic controls at 18 months)(Clayton et al., 2015). 
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Autofluorescent aggregates were identified in neurons and microglia and were shown to be 
surrounded by LAMP-1 and LAMP-2 positive membranes, suggesting they are endosomal in 
origin. Accumulation of ubiquitin positive inclusions and an increase in insoluble p62 was 
also observed in a mouse model described by Gascon et al., 2014, in which CHMP2BIntron5 
was expressed within forebrain neurons, using a tetracycline inducible Calcium/Calmodulin 
Dependent Protein Kinase II Alpha (CamK2a) promoter system (Gascon et al., 2014). A third 
CHMP2BIntron5 mouse model was described by Vernay et al., (2016) (Vernay et al., 2016). 
This mouse expressed human CHMP2BIntron5 under the control of the mouse Thy1.2 
promoter, a promoter proposed to express strongly in central and peripheral neurons, 
including both cortical and motor neurons. Whilst heterozygous expression of CHMP2BIntron5 
showed mRNA levels comparable to endogenous CHMP2B, mRNA levels were 3.4-fold 
higher in homozygotes. Semi-quantitative analysis demonstrated that both hetero and 
homozygous mice show an age-dependent accumulation of ubiquitin and p62 aggregates 
with the nervous system (Frontal cortex, corpus callosum, thalamus, brainstem and spinal 
cord). It must be noted that in contrast to previous studies, in which CHMP2BIntron5 mice were 
compared to mice overexpressing CHM2BWild type at the same genomic locus, this study 
looked at both heterozygous and homozygous CHMP2BIntron5 versus non-transgenic 
controls.  
Autophagy. 
Accumulation of aggregated proteins in neurodegenerative disorders has been suggested to 
be caused, at least in part, by the decline of cellular degradative processes, notably 
autophagy (Monaco and Fraldi, 2020). Autophagosome accumulation has been identified as 
a common feature of CHM2B-related FTD models (Table 1). Microtubule-associated protein 
1A/1B-light chain 3 (LC3) positive autophagosomes were observed in CHMP2BIntron5 
transfected rat cortical neurons using GFP-LC3 (Lee et al., 2007; Lee and Gao, 2009). 
These GFP-LC3 positive autophagosomes were shown to form after the initial appearance 
of ubiquitylated-protein-containing vesicles (Lee et al., 2007). Monitoring autophagic flux, 
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using the pH-sensitive tandem tagged GFP-mCherry-LC3 dual colour construct (Pankiv et 
al., 2007), also revealed expression of CHMP2BIntron5 in rat primary neurons resulted in an 
aberrant accumulation of large GFP-mCherry-LC3 double labelled puncta, suggesting an 
impairment of autophagosome-lysosome fusion (West et al., 2020). In contrast, neurons 
expressing wild type CHMP2B rarely showed GFP positive puncta, indicating normal 
autophagosome-lysosome fusion leading to quenching of the pH-sensitive GFP tag. These 
observations were recapitulated in vivo using Drosophila, identifying autophagosome 
accumulation and dysfunctional phagosomal-lysosomal fusion as a conserved feature of 
CHMP2BIntron5 pathology (West et al., 2020).  
 
Autophagosome accumulation in CHMP2BIntron5 neurons has been proposed to be a 
contributing factor in neuronal cell death (Filimonenko et al., 2007; Lee et al., 2007; Lee and 
Gao, 2008). Pharmacological inhibition of autophagy, using 3-Methyladenine, or genetic 
knockdown of ATG5 and ATG7 was shown to delay CHMP2BIntron5 induced neuronal cell 
loss (Lee and Gao, 2009). It is important to note however, that despite the prevention of cell 
death, inhibition of autophagy does not rescue the endosomal hallmarks associated with the 
mutation, suggesting that deficits in endo-lysosomal trafficking may cause 
neurodegeneration independent of the neurons autophagic status (Lee and Gao, 2009). 
Recent evidence demonstrated the FDA approved compound Ursodeoxycholic Acid (UDCA) 
as a potent neuroprotectant in Drosophila and primary neuronal models of CHMP2BIntron5. 
UDCA was shown to act downstream of defective endosomal/lysosomal and 
autophagosomal trafficking, suggesting novel potential therapeutic targets also exist 
downstream of endosomal-lysosomal and autophagic dysfunction (West et al., 2020).  
 
Neuronal Homeostasis and Cell Death. 
In addition to impaired proteostasis associated with perturbations to the endosomal-
lysosomal and autophagic trafficking pathways, CHM2PB has also been implicated in 
neuronal homeostasis (Table 1). The importance of CHMP2B in neuronal homeostasis 
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became evident when CHMP2BIntron5 and CHMP2B〉10 mutations were expressed in primary 
cortical neurons. Ectopic expression of CHMP2BIntron5 caused severe dendritic retraction 
after three days in culture (Lee et al., 2007). Concomitant experiments where neurons 
expressed CHMP2B〉10 or CHMP2BD148Y showed minimal dendrite loss (Lee et al., 2007). 
CHMP2BIntron5 has also been demonstrated to decrease the number of mushroom spines in 
primary neurons (Belly et al., 2010).  
 
Supporting a role for CHMP2BIntron5 in perturbed neuronal homeostasis in vivo, an increase in 
the number of immature spines was observed in pyramidal neurons in the medial prefrontal 
cortex of CHMP2BIntron5 mice (Gascon et al., 2014). This was accompanied by an age-
dependent downregulation of miR-124 and a concomitant dysregulation of AMPAR subunit 
composition, correlating with the age of onset of behavioural phenotypes (Gascon et al., 
2014). miR-124 downregulation and concomitant increase in AMPARs was also shown in 
iPSC-derived cortical neurons and in the frontal cortex of bvFTD patients (Gascon et al., 
2014). Electrophysiological analysis suggests social deficits in CHMP2BIntron5 mice was 
linked to an increase in Ca2+-impermeable AMPARs at excitatory synapses of pyramidal 
neurons in the prefrontal cortex. Dysregulation of AMPAR subunit composition has been 
implicated in a number of ALS variants including C9orf72 and SOD1, as well as sporadic 
ALS cases (Gregory et al., 2020; Kawahara et al., 2003; Kwak et al., 2010). Variation in 
which AMPAR subunits are up- or down-regulated may provide insight into both converging 
and diverging mechanisms in different FTD and ALS variants. Endosomal-lysosomal 
trafficking and sorting of AMPARs in MVBs plays a critical role in AMPAR dynamics and 
synaptic homeostasis (Parkinson and Hanley, 2018). Ubiquitination and efficient sorting of 
AMPARs allows targeted recycling, sorting and degradation of AMPARs within neurons. 
Endosomal-lysosomal dysfunction therefore underpins a number of neurodegenerative 
diseases, resulting in aberrant AMPAR recycling and degradation. Approaches to rectify the 
altered trafficking of AMPARs as a result of endosomal-lysosomal dysfunction are therefore 
a significant target for therapeutic intervention. As such elucidating the role of CHMP2B and 
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ESCRT machinery in AMPAR dynamics in CHMP2B-related FTD-ALS represents an 
important area of research with implications across the disease spectrum. 
 
In addition to perturbed neuronal structure and function, expression of CHMP2BIntron5 has 
been implicated in neuronal death and upregulation of apoptotic cascades in both in vitro 
and in vivo models. Drosophila pan-neuronally expressing CHMP2BIntron5 display increased 
levels of p53 and cleaved DCP-1, the fly homolog of caspase 3 (West et al., 2020; West et 
al., 2018). Elevated levels of p53 mRNA have also been shown in patient-derived iPSC 
neurons (Zhang et al., 2017). This was shown to be reduced when the CHMP2BIntron5 
mutation is isogenised with CRISPR/Cas9 (Zhang et al., 2017). Furthermore, neuroepithelial 
cells expressing CHMP2BIntron5 display increased levels of cleaved caspase 3, a key 
regulator of apoptosis, suggesting that neuronal cell death may be regulated by the 
p53/caspase 3 pathway (West et al., 2018). Neuronal cell death has also been observed in 
mouse models. At 18 months, mice showed a significant loss of thalamic and cortical 
volume, coupled with a significant reduction in the number of neurons present within the 
thalamus (Clayton et al., 2017). Aberrant accumulation of POSH/SH3RF1, a known regulator 
of JNK-dependent apoptotic cascades was also observed in the Gascon mouse model and 
in Drosophila pan-neuronally expressing CHMP2BIntron5 (West et al., 2018). POSH/SH3RF1 
has also been implicated in the regulation of calcium homeostasis and immune signalling 
cascades, providing a potential link between neuronal homeostasis, apoptosis and immune 
signalling in FTD/ALS. 
Immunity. 
The first in vivo model of FTD3 was the Drosophila CHMP2BIntron5 model reported by the Gao 
and Sweeney labs (Ahmad et al., 2009). This model used the UAS/Gal4 system to allow 
cell/tissue specific control of CHMP2BIntron5 expression in Drosophila and has formed the 
foundation for a number of significant studies elucidating the molecular mechanisms 
underpinning CHMP2BIntron5 associated toxicity, in vivo (Ahmad et al., 2009; Cheruiyot et al., 
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2014; Fort-Aznar et al., 2020; Lee et al., 2019; Lu et al., 2020; Lu et al., 2013; West et al., 
2015; West et al., 2020; West et al., 2018; Wilson et al., 2020). Many of these studies 
utilised the genetic power of Drosophila for genome wide, in vivo, modifier screens, followed 
by genetic dissection of identified modifier loci. Having previously demonstrated, in vitro, that 
CHMP2BIntron5 toxicity resulted from a failure of CHMP2B to dissociate from CHMP4B (Lee et 
al., 2007) Ahmad et al., (2009) showed that expression of a GFP tagged Shrub (the 
Drosophila CHMP4B orthologue), which acts as a dominant negative, phenocopied 
CHMP2BIntron5 (Ahmad et al., 2009).  An unbiased, dominant genome-wide (covering ~75% 
of the Drosophila genome), modifier screen using expression of shrub-GFP in the fly eye 
identified 29 potent modifier loci. Secondary screens tested strong shrub-GFP enhancers 
against CHMP2BIntron5 expression. The initial screen employed chromosomes carrying large 
defined deletions (Ryder et al., 2007), followed by more refined deletions and finally 
individual gene mutations to identify genes that, when heterozygous, dominantly enhanced 
or suppressed the CHMP2BIntron5 eye phenotype. Analysis of individual loss-of-function 
alleles covered by the strongest enhancer (Df(3R)ED5664), a deletion on the right arm of 
chromosome 3 covering 55 genes (2 partially), demonstrated loss of function of the serine 
protease inhibitor Serpin 88Ea (Serpin 88Ea/Serpin5) as a potent enhancer of CHMP2BIntron5 
toxicity. Spn88Ea overexpression partially rescued CHMP2BIntron5 toxicity (Ahmad et al., 
2009). Characterisation of Spn88Ea identified it to be a negative regulator of Toll signalling 
pathways, leading to the observation of a 3.4 fold increase in Toll (Both the toll receptor and 
the toll ligand cleaved-spaetzle) in the heads of CHMP2BIntron5 flies. This increase was 
coupled with an elevation of the Drosophila antimicrobial peptide, drosomycin, a 
transcriptional target of Toll. Together these findings identified Toll signalling as a major 
signalling pathway disrupted by CHMP2BIntron5 in vivo (Ahmad et al., 2009).  
As part of the same genome wide modifier screen that identified Spn88Ea, West et al., 
(2015) identified that mutations in the small GTPase Rab8 significantly potentiated 
CHMP2BIntron5 toxicity (West et al., 2015). Rab8 is a known interactor of Optineurin (OPTN) 
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and was subsequently identified as a downstream target of C9orf72 GDP/GTP exchange 
factor activity, identifying potential common pathways in ALS disease pathology (Corbier and 
Sellier, 2017; Hattula and Peranen, 2000). Analysis of synaptic morphology at the 
Drosophila 3rd instar larval neuromuscular junction, revealed synaptic overgrowth in Rab8 
mutants was driven by aberrant JNK and TGFく signalling (West et al., 2015). Elevated JNK 
signalling was mediated by TAK1 and POSH/SH3RF1, which together form part of the 
Drosophila Immune deficiency (IMD) signalling pathway, a component of the Drosophila 
innate immune system homologous to mammalian TNFR signalling (Tsuda et al., 2005). 
POSH/SH3RF1 was subsequently shown to accumulate within the nervous system of both 
Drosophila and mouse CHMP2BIntron5 models, mediating aberrant JNK-dependent apoptotic 
cascades (West et al., 2018). Knockdown of POSH/SH3RF1 was sufficient to alleviate 
aberrant synaptic growth at the Drosophila larval NMJ, in larvae pan-neuronally expressing 
CHMP2BIntron5, as well as early pupal/pharate lethality. POSH/SH3RF1 shRNA knockdown 
could also alleviate dendritic collapse in primary mammalian neurons transfected with 
CHMP2BIntron5. Studies have also shown that POSH/SH3RF1 directly interacts with and can 
ubiquitinate PDCD6IP/ALIX, which in turn has been shown to associate with and regulate 
ESCRT assembly (Christ et al., 2016; Votteler et al., 2009).   
In a more recent targeted screen looking at the genetic interaction between known FTD and 
ALS loci, I-kappaB kinase i (IKKi/IK2), the Drosophila orthologue of Tank-binding kinase 1 
(TBK1), was identified as a potent modifier of CHMP2BIntron5 (Lu et al., 2020). TBK1, an IKK 
kinase, has been implicated in the regulation of both immune signalling cascades and 
autophagy, in part through phosphorylation of OPTN (Richter et al., 2016). As such, genetic 
interaction between CHMP2BIntron5 and TBK1 further underlines potential interplay between 
autophagic and immune signalling pathways in FTD-ALS spectrum disorders. These findings 
also contribute to a developing framework of known FTD-ALS loci and interactors, including 
TBK1, OPTN, CHMP2B, Rab8, Ubiquilin-2 and C9Orf72 involved in these pathways.  
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All three CHMP2BIntron5 mice models have been reported to display gliosis, supporting a 
conserved role of immune signalling cascades in neurodegeneration (Gascon et al., 2014; 
Ghazi-Noori et al., 2012; Vernay et al., 2016). At just 3 months of age the mouse model 
reported by Ghazi-Noori et al., (2012) showed a significant increase in Iba-1 positive 
microglia throughout the hippocampus and thalamus. By 18 months, gliosis was 
accompanied by a significant increase in pro-inflammatory cytokines (Clayton et al., 2017).  
Taken together these studies elucidate novel components of immune signalling cascades 
that interact with, or are regulated by, the ESCRT machinery and contribute towards 
neurodegeneration in CHMP2BIntron5 models of FTD-ALS. Perturbed immune signalling 
pathways, neuroinflammation and microgliosis are common across the FTD-ALS spectrum 
(McCauley and Baloh, 2019). Unravelling the mechanisms by which CHMP2BIntron5 elicits 
aberrant immune activation may identify conserved regulators of neurodegeneration and 
potential therapeutic targets. 
Other Mechanisms.  
Studying CHMP2B from the perspective of basic biology and disease, has demonstrated the 
profound effect CHMP2B has in the regulation of neuronal homeostasis, proteostasis and 
immune signalling cascades. Models of CHMP2BIntron5 have also identified more diverse, 
overlapping, biological mechanisms at play, with broad relevance across the FTD-ALS 
spectrum. 
The majority of genome wide screens in Drosophila used the eye specific driver GMR-Gal4 
to express CHMP2BIntron5 in the fly eye. A recent study demonstrated GMR-Gal4 also drives 
expression in a subset of timeless expressing neurons in the Drosophila optic lobe (Lee et 
al., 2019). Expression of CHMP2BIntron5 in these neurons causes a reduction of timeless 
transcripts during light periods and a shortening of locomotor free running during dark:dark 
cycles (Lee et al., 2019). These findings suggest CHMP2BIntron5 can disrupt the function of 
the circadian clock. While classical ALS and FTD symptoms may directly perturb sleep, a 
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growing body of evidence suggests that circadian dysfunction is not merely a symptom and 
may actually drive pathogenesis early in the course of neurodegeneration. This has been 
observed in a number of neurodegenerative disorders where disturbances have been shown 
to precede classical symptoms (Musiek and Holtzman, 2016; Videnovic et al., 2014). Recent 
studies have also shown a critical, bidirectional interplay between the circadian clock and 
biological mechanisms, including inflammation, proteostasis, metabolism and redox 
homeostasis during neurodegeneration (reviewed in Musiek and Holtzman (2016) and 
Videonovic et al., (2014)).  
 
Few groups have monitored the oxidative stress burden in CHMP2BIntron5 cells, however 
oxidative stress has long been linked to neurodegeneration in FTD and ALS. Deficits in 
redox homeostasis have been identified by Zhang et al., (2017) in iPSC derived neurons 
from CHMP2BIntron5 patients. This is an important and useful tool for the field, given the rare 
nature of the mutation and subsequent lack of patient tissue. This in vitro model identified 
aberrant endosomes and mitochondria in CHMP2BIntron5 neurons compared to CHMP2BWild 
type controls. CHMP2BIntron5 mitochondria in patient neurons had substantial deficits in 
mitochondrial capacity, including significant reductions in basal and maximum respiration as 
well as spare respiratory capacity. These deficits were alleviated when the CHMP2BIntron5 
mutation was repaired using CRISPR/Cas9. Transcriptomic analysis of CHMP2BIntron5 
neurons, compared to isogenic controls, identified a cluster of genes known to be involved in 
iron homeostasis. It was posited that deficits in iron homeostasis may increase intracellular 
ferrous ions (Fe2+), contributing to the ongoing endosomal pathology (Zhang et al., 2017). 
Consistent with this hypothesis, a significant increase in intracellular Fe2+ was identified in 
CHMP2BIntron5 neurons, compared to isogenic controls. A significant increase in the protein 
level of transient receptor potential channel 6 (TRPC6), a channel implicated in iron and zinc 
uptake in PC12 cells and primary cortical neurons, was also observed (Knutson, 2019; 
Mwanjewe and Grover, 2004; Zhang et al., 2017). Impaired iron metabolism and 
homeostasis has been implicated in a number of neurodegenerative disorders including 
Jo
ur
na
l P
re
-p
ro
of
Journal Pre-proof
19 
 
Parkinson’s disease, Huntington’s disease and ALS (Muller and Leavitt, 2014; Petillon et al., 
2018; Yu et al., 2018). Furthermore, lysosomal degradation and autophagy have been 
shown to play an important role in the regulation of iron levels and iron metabolism (Jacomin 
et al., 2019; Kurz et al., 2008). In a more recent study it was found that Drosophila models 
pan-neuronally expressing CHMP2BIntron5 exhibited a significant increase in the Glutathione 
S-Transferase D1-GFP reporter (West et al., 2020). Furthermore, overexpression of the 
catalytic and modifying subunits of glutamate cysteine ligase (GCL) prevents dendritic 
retraction in CHMP2BIntron5 expressing primary rat neurons, suggesting that dendrite 
pathology may be linked to defective redox homeostasis (West et al., 2020). Pan-neuronal 
co-expression of the catalytic subunit of GCL (GCLC) with CHMP2BIntron5 was also sufficient 
to rescue perturbed neuronal morphology at the Drosophila third instar neuromuscular 
junction, as well as impaired locomotor function in these larvae. Impaired locomotor function, 
characterised both by reduced crawling velocity and directional indecision is a well 
characterised phenotype in CHMP2BIntron5 fly models (West et al., 2020; West et al., 2018). 
Behavioural deficits representative of both FTD and ALS phenotypes have also been 
reported in all three CHMP2BIntron5 mouse models. Mice reported by Ghazi-Noori et al., 
(2012) displayed social and motor deficits at 18 months of age, correlating with a significant 
loss of thalamic and cortical volume, coupled with a significant reduction in the number of 
neurons present within the thalamus (Clayton et al., 2017). The Gascon et al., (2014) mice 
displayed a significant, age-dependent, selective impairment in sociability with roughly 20% 
of mice also showing a compulsive grooming phenotype, suggesting additional behavioural 
deficits. Age-dependent motor impairment and behavioural perturbations, as well as a 
significant reduction in longevity, compared to non-transgenic litter-mates, was also 
observed in mice described by Vernay et al., (2016). 
 
In addition to neurodegenerative phenotypes CHMP2BIntron5 models have also highlighted a 
functional role for CHMP2B in developmental processes. In 2014 Cheruiyot et al., modified 
the previously described UAS-CHMP2BIntron5 construct (Ahmad et al., 2009) to introduce an 
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N-terminal Flag tag, which was subsequently injected into Drosophila to generate a new 
transgenic line (UAS-Flag-CHMP2BIntron5). As both this and the original UAS-CHMP2BIntron5 
fly lines were generated through random integration into the genome, as opposed to site-
directed approaches, the UAS-Flag-CHMP2BIntron5 and original UAS-CHMP2BIntron5 will be 
located in different regions of the genome. These lines will therefore have potential 
variances in expression. Indeed Cheruiyot et al., (2014) showed Flag tagged CHMP2BIntron5 
was expressed more strongly than the untagged CHMP2BIntron5 line. Expression of both 
models under the control of the eyeless-gal4 driver, which drives earlier in development and 
in a distinct population of cells to the GMR-gal4 driver used in previous studies, revealed 
developmental perturbations to the fly eye and photoreceptor patterning. Further 
characterisation revealed these phenotypes were mediated by increased Notch signalling, 
with notch accumulating in Rab5 and Rab7 positive endosomes. In a subsequent study 
Wilson et al., (2019) demonstrated neurodevelopmental defects associated with ectopic 
expression of CHMP2BIntron5, revealing Notch dependent defects in cell fate determination 
(Wilson et al., 2020). In addition to supporting previous observations that CHMP2BIntron5 
mediated perturbations to endosomal-lysosomal trafficking significantly impairs normal 
receptor homeostasis, these findings contribute to an increasing number of studies 
implicating altered Notch signalling in FTD-ALS neurodegeneration (Gomez-Pinedo et al., 
2019; Liu et al., 2020; Nonneman et al., 2018; Wang et al., 2015; Yang et al., 2015). Further 
studies will be important in elucidating the contribution of the many pathways regulated by 
Notch, including cell fate, growth, migration, synaptic plasticity and neuronal survival, in 
neurodegenerative cascades in FTD-ALS spectrum disorders. 
Pharmacological Rescue of CHMP2BIntron5 and Implications for FTD-ALS Spectrum 
Disorders. 
Since the initial identification of CHMP2BIntron5 as a causative FTD locus, a combination of in 
vitro and in vivo models have greatly contributed to our understanding of the molecular 
mechanisms underpinning CHMP2BIntron5-related neurodegeneration. Although a rare cause 
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of FTD and ALS, the fundamental role of CHMP2B and the ESCRT machinery in the 
regulation of neuronal proteostasis, endosomal-lysosomal and autophagic trafficking events, 
means that models of CHMP2B have also contributed to our understanding of the 
mechanisms driving neurodegeneration across the FTD-ALS spectrum more broadly. 
Identification of novel therapeutics that prevent or delay neurodegeneration associated with 
CHMP2BIntron5 mutations are therefore of potential significance to other monogenic and 
sporadic forms of FTD-ALS. 
Two recent studies combining the use of Drosophila and mammalian primary neuron models 
have identified compounds acting on distinct molecular pathways to alleviate toxicity in 
CHMP2BIntron5 models. The first of these studies identified a potential role for antiretroviral 
compounds in the treatment of CHMP2BIntron5 FTD-ALS. Using their unbiased genetic screen 
in Drosophila, Fort-Aznar et al., (2020) identified mutations in genes functioning in retrovirus 
(RV) repression as dominant modifiers of CHMP2BIntron5 (Fort-Aznar et al., 2020). RV’s are 
genetically mobile elements, present in most eukaryotic genomes that accumulate in 
heterochromatic regions (Saito et al., 2006). Their ability to replicate, transpose and infect 
other cells is controlled by a complex cellular network of RV repressors, which prevent RV 
activation. Deficits in RV silencing machinery are thought to occur in different 
neurodegenerative pathologies, particularly FTD-ALS, where increases in RV expression 
have been observed in patient tissue (Douville and Nath, 2017; Li et al., 2015). 
Furthermore, an increase in the reverse transcriptase activity of human endogenous RV 
(HERV)-K, has been identified in cerebrospinal fluid from ALS patients (Andrews et al., 
2000; MacGowan et al., 2007; McCormick et al., 2008; Steele et al., 2005; Viola et al., 
1975). For these reasons, nucleoside reverse transcriptase inhibitors have been used as 
potential therapeutic treatments for ALS (Gold et al., 2019). In this study the authors found 
expression of CHMP2BIntron5 led to an increase in RV translocation events and an 
accumulation of the gypsy RV in the Drosophila brain (Fort-Aznar et al., 2020). Furthermore 
they found that pharmacological inhibition of viral reverse transcriptase activity (using 
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Stavudine or Lamivudine) was sufficient to alleviate degenerative phenotypes in rat primary 
neuron models of CHMP2BIntron5 (Fort-Aznar et al., 2020). This study was the first to 
demonstrate that RV de-repression occurs in CHMP2BIntron5 models. However a similar study 
found that glial expression of hTDP-43 in Drosophila resulted in de-repression and activation 
of gypsy, leading to glial secretion of toxic factors driving DNA damage and apoptotic 
cascades in adjacent neurons (Chang and Dubnau, 2019). Taken together these studies 
highlight convergent mechanisms that may underpin spreading pathology in FTD-ALS and 
other neurodegenerative diseases. This data also suggests that nucleoside reverse 
transcriptase inhibitors may represent novel treatments for CHMP2BIntron5 and other FTD-
ALS spectrum diseases. Future work on this topic will likely benefit from data monitoring the 
effects of these drugs in patients across the FTD-ALS spectrum. A phase 2a trial in Australia 
determined the safety and tolerability of Triumeq, a combination therapy consisting of 
dolutegravir (50mg) abacavir (600mg) and lamivudine (300mg). Overall, this combination 
therapy was well tolerated, with no drug related adverse effects described (Gold et al., 
2019). A significant decrease in HERV-K expression was observed accompanied by a 
decline in the ALS functioning rating scale-revised (ALSFRS-R) progression rate of 21.8%. 
Based on these reports, a phase 3 trial will be planned. Similarly, a phase 1 proof of concept 
trial is now recruiting, testing the efficacy of four antiretroviral compounds (darunavir, 
ritonavir, dolutegravir, tenofovir alafenamide) in ALS patients (see ClinicalTrials.gov 
Identifier: NCT02437110) . 
In a second study it was demonstrated that the FDA approved compound, UDCA and 
Ursocholanic acid (UCA), a structurally related compound, prevent neuronal cell death in 
Drosophila and mammalian models of CHMP2BIntron5. UDCA is a natural hydrophilic bile acid 
produced in the pancreas as tauro-ursodeoxycholic (TUDCA), and processed in the gut to 
UDCA and has been shown to ameliorate mitochondrial dysfunction in Parkinson’s and 
Alzheimer’s patient fibroblasts, albeit through an unknown mechanism (Bell et al., 2018; 
Mortiboys et al., 2015). UDCA and UCA ameliorated aberrant NMJ morphology and crawling 
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deficits in Drosophila larvae pan-neuronally expressing CHMP2BIntron5 (West et al., 2020). 
Both compounds also prevented dendritic collapse phenotypes associated with 
overexpression of CHMP2BIntron5 in rat primary neurons. Interestingly, UDCA did not affect 
any of the endo-lysosomal or autophagic hallmarks associated with the mutation, indicating it 
may act downstream of perturbed endosomal dysfunction and proteostasis. UDCA has 
previously been shown to negatively regulate p53 transcription and assembly, ultimately 
preventing apoptosis (Amaral et al., 2007; Amaral et al., 2010). UDCA prevented p53 and 
cleaved caspase 3 accumulation in CHMP2BIntron5 Drosophila models. RNA sequencing of 
CHMP2BIntron5 larvae revealed that UDCA positively regulates GCLC, the rate limiting 
enzyme in glutathione synthesis, suggesting that along with reducing p53, UDCA may 
influence neuronal redox homeostasis. UDCA has also been shown to exhibit anti-
inflammatory activity further supporting the hypothesis that neurodegeneration in 
CHMP2BIntron5, and FTD-ALS spectrum disorders more broadly, may be mediated by 
dynamic interplay between redox homeostasis, immune signalling, endosomal-lysosomal 
and autophagic trafficking and apoptotic cascades. 
The identification that UDCA appears to act downstream of endosomal-lysosomal 
dysfunction and the classical hallmarks of CHMP2BIntron5 suggests it may have a broad 
neuroprotective function. As such, therapeutics similar to UDCA may have broader 
relevance across the FTD-ALS spectrum and other neurodegenerative pathologies. This is 
evidenced by a number of clinical trials monitoring UDCA and it’s taurine conjugate form, 
TUDCA in ALS (Trial Number NCT00877604) and Parkinson’s Disease (Trial Number 
NCT03840005) patients. 
Conclusion. 
Since its identification as an FTD-ALS locus over 15 years ago, the study of mutations in 
CHMP2B have helped define its role in endo-lysosomal and autophagic proteostasis, 
immune signalling cascades and neuronal homeostasis, in both health and disease. 
Although mutations in CHMP2B are rare, deploying CHMP2B as a model to understand why 
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these defects in endosomal trafficking and proteostasis cause disease, has provided insights 
into the complex mechanistic biology that causes neuronal cell loss. Furthermore, in vitro 
and in vivo models have identified a number of potential therapeutic targets and novel small 
molecules that ameliorate neurodegeneration. The CHMP2B chapter is far from closed, and 
as we uncover more about the functions of CHMP2B and ESCRT-III, we enhance our 
understanding of both FTD-ALS spectrum disorders and mechanisms underpinning 
neurodegeneration. 
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Figure 1. CHMP2B Structure and Function.
 
 
 
A. CHMP2B gene schematic showing some of the mutations associated with FTLD (D148Y 
(Semantic Dementia, Green), Q165X and M178V (CHMP2BIntron5) (bvFTD, Blue)) and Motor 
Neurone Disease (I29V, T104N and Q206H (Primary Muscular Atrophy, Red)). B. CHMP2B 
is a 213 amino acid protein containing two N-terminal coiled coil domains (CC) (1-50 and 
120-150) and a C-terminal MIT-interacting motif (MIM) essential for interacting with Vps4. 
The FTLD mutation M178V results in two C-terminally truncated proteins, CHMP2B〉10 and 
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CHMP2BIntron5, resulting in a loss of the MIM domain and acidic alpha helices, reducing auto 
inhibition.  
C. CHMP2B is a core component of ESCRT-III, which acts sequentially with other ESCRTs 
in the biogenesis of multivesicular bodies (MVB’s) and the sorting of ubiquitinated cargo into 
intraluminal vesicles during endosomal-lysosomal trafficking. The altered C-terminus of 
CHMP2BIntron5 prevents membrane scission, leading to accumulation of deformed MVB’s 
containing ubiquitinated proteins, incapable of fusing with the lysosome. Adapted from 
“Generic Endocytic Pathway”, by BioRender.com (2020). Retrieved from 
https://app.biorender.com/biorender-templates. 
 
Table 1. Phenotypes Observed in Different CHMP2BIntron5 Models 
Pathway Phenotype Model Reference 
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Ubiquitin and/or p62 aggregates 
 
 
 
 
 
 
HeLa Filimonenko et al., 2007 
 
Fly & Rat Primary Neurons West et al., 2020 
 
Rat Primary Neurons Lee et al., 2007  
 
Rat Primary Neurons Lee and Gao, 2009 
 
Mouse Ghazi-Noori et al., 2012 
 
Mouse Gascon et al., 2014 
 
Mouse Vernay et al., 2016 
 
   Accumulation of Enlarged Autophagosomes 
 
Rat Primary Neurons Lee et al., 2007  
 Rat Primary Neurons Lee and Gao, 2009 
 HeLa Filimonenko et al., 2007 
 Fly & Rat Primary Neurons West et al., 2020 
 
Accumulation of Enlarged Endosomes 
 
 
 
 
 
 
Rat Primary Neurons Lee et al., 2007  
 
Patient Fibroblasts Nielsen et al., 2012 
 
Rat Primary Neurons Lee and Gao, 2009 
 
PC12 Skibinski et al., 2005 
 
Patient fibroblasts & cortex Urwin et al., 2010 
 
iPSC Zhang et al., 2017 
 
Fly & Rat Primary Neurons West et al., 2020 
 
Mouse Ghazi-Noori et al., 2012 
 
dendritic retraction Rat primary neurons West et al., 2020 
 
dendritic retraction Rat primary neurons Lee et al., 2007 
 
decrease the number of mushroom spines Rat primary neurons Belly et al., 2010 
 
elevated p53 iPSC Zhang et al., 2017 
 
elevated p53 Fly West et al., 2020 
 
elevated apoptosis markers Fly and Rat GPNT West et al., 2018, West et al., 2020 
 
Perturbed Neuronal Growth/Moprhology Fly West et al., 2015 
 
neuronal cell loss / cortical volume Mouse Clayton et al., 2017 
 
increase in immature spines and dysregulation of 
AMPAR composition Mouse Gascon et al., 2014 
 
Impaired neuromuscular function and distal 
axonopathy  Mouse Vernay et al., 2016 
 
Increase in Toll signalling  Fly Ahmad et al., 2009 
 
Accumulation of SH3RF1/POSH Fly & Mouse West et al., 2018 
 
Genetic Interaction between CHMP2B and TBK1 Fly Lu et al., 2020 
 
gliosis and proinflamatory cytokine elevation Mouse Clayton et al., 2017 
 
gliosis Mouse Gascon et al., 2014 
 
gliosis Mouse Vernay et al., 2016 
 
motor / behavioural dysfunction Fly West et al., 2020 
 
motor / behavioural dysfunction Mouse Clayton et al., 2017 
 
motor / behavioural dysfunction Mouse Gascon et al., 2014 
 
motor / behavioural dysfunction Mouse Vernay et al., 2016 
 
redox dysfunction iPSC Zhang et al., (2017) 
 
redox dysfunction Fly and Rat neuroepithelial West et al., 2020 
 
circadian dysfunction Fly  Lee et al., 2019 
 
developmental dysfunction Fly Cheruiyot et al., 2014 
 
developmental dysfunction Fly Wilson et al., (2019) 
 
Impaired retroviral silencing Fly and Rat primary neurons Fort-Aznar et al., 2020 
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